• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Hematol Rep . COVID-19 and blood groups: A six-months observational study in Ferrara, Italy

tetano

Editor, Senior Moderator
Hematol Rep


. 2021 Sep 6;13(3):9177.
doi: 10.4081/hr.2021.9177.
COVID-19 and blood groups: A six-months observational study in Ferrara, Italy


Salvatore Greco[SUP] 1 [/SUP], Nicolò Fabbri[SUP] 2 [/SUP], Alessandro Bella[SUP] 1 [/SUP], Beatrice Bonsi[SUP] 1 [/SUP], Alessandra Violi[SUP] 1 [/SUP], Valeria Fortunato[SUP] 1 [/SUP], Maurizio Govoni[SUP] 3 [/SUP], Giuseppe Graldi[SUP] 3 [/SUP], Angelina Passaro[SUP] 1 4 [/SUP]



Affiliations

Abstract

The current literature still gives a little information about the relationships between the ABO blood group system and the immune response to the virus or the different disease outcomes. Hypothesizing the presence of a predisposition by some blood groups to COVID-19, we searched for differences between patients towards the different outcomes of disease.We enrolled 330 inpatients with a diagnosis of COVID-19, determining both their ABO blood group system and Rh factor, collecting demographic, clinical and laboratory data. We searched for relationships with COVID-19 outcomes within an observation period of 180 days (Intensification of Care - IoC, Inhospital death, 180-days mortality). The most frequent ABO blood group was A (45.8%); a minor part was represented by group O (38.8%), B (11.5%), AB (3.9%). As for the Rh factor, 86.7% of patients were Rh-positive. There were no significant differences between blood groups and Rh factors as for age, length of hospital stays (LoS), or Charlson Comorbidity Index (CCI), nor we found significant relationships between the ABO groups and COVID-19 outcomes. A significant relation was found between AB group and IoC (p=0.03) while as for the Rh factor, the patients with Rh factor positive died with less frequency during the stay (p=0.03). Cox regression analyses showed substantial differences in the survival functions concerning the Rh factors. The Rh factor seems to be involved in the 180-day prognosis. The survival functions of patients with Rh factor positive show, in fact, significantly better curves when compared to those with Rh factor negative.

Keywords: ABO; COVID-19; Coronavirus; Rh factor; blood group.
 
Back
Top Bottom